Pharmacology Explained: How Drugs Work in the Body

What Pharmacology Actually Studies

Pharmacology is the branch of biomedical science that studies the effects of chemical substances on living organisms, with a particular focus on how those substances can be used to treat, prevent, or diagnose disease. The word itself comes from the Greek pharmakon, meaning drug or medicine, and logos, meaning knowledge or study. Unlike pharmacy, which focuses on the preparation and dispensing of medications, pharmacology is concerned with the underlying mechanisms: how a drug molecule enters the body, reaches its target, produces an effect, and is eventually eliminated.

The discipline splits into two fundamental branches. Pharmacokinetics describes what the body does to a drug, covering absorption, distribution, metabolism, and excretion (often abbreviated ADME). Pharmacodynamics describes what the drug does to the body, including receptor binding, signal transduction cascades, and the physiological responses that follow. Together, these two branches explain the complete life cycle of a drug from the moment it enters the body to the moment its last metabolite is cleared.

Pharmacology emerged as a distinct scientific discipline in the nineteenth century, though humans have used plant-derived medicines for thousands of years. Opium, derived from the poppy Papaver somniferum, has been used for pain relief since at least 3400 BCE. Willow bark, containing the precursor to aspirin, was chewed for headaches in ancient Egypt. However, the systematic study of drug action began with Rudolf Buchheim, who established the first pharmacology laboratory in Dorpat (now Tartu, Estonia) in 1847, and his student Oswald Schmiedeberg, who is often called the father of modern pharmacology.

Modern pharmacology intersects with nearly every branch of biology and medicine. Toxicology, the study of the harmful effects of chemicals, is essentially pharmacology in reverse, examining how substances cause damage rather than therapeutic benefit. Clinical pharmacology applies pharmacological principles directly to patient care, determining optimal dosing regimens and managing drug interactions. Neuropharmacology focuses specifically on drugs that affect the nervous system, while cardiovascular pharmacology studies drugs that act on the heart and blood vessels. Each of these specializations contributes to a unified understanding of how chemical agents interact with biological systems.

Pharmacokinetics: What the Body Does to Drugs

Once a drug enters the body, it must navigate a complex journey before it can reach its target and produce an effect. Pharmacokinetics tracks this journey through four sequential phases: absorption, distribution, metabolism, and excretion.

Absorption is the process by which a drug moves from its site of administration into the bloodstream. For orally administered drugs, this primarily occurs in the small intestine, whose vast surface area (approximately 250 square meters due to villi and microvilli) and rich blood supply make it ideal for absorbing molecules. The rate and extent of absorption depend on the drug's chemical properties, particularly its lipophilicity (fat solubility) and ionization state. Lipophilic molecules cross cell membranes more easily because the lipid bilayer itself is hydrophobic. The Henderson-Hasselbalch equation predicts what fraction of a drug will be in its unionized (absorbable) form at a given pH, which is why the stomach's acidic environment favors absorption of weakly acidic drugs, while the small intestine's more alkaline pH favors weakly basic drugs.

Distribution describes how a drug spreads throughout the body after reaching the bloodstream. Factors affecting distribution include blood flow to various organs, the drug's ability to cross membrane barriers (such as the blood-brain barrier), and the extent to which the drug binds to plasma proteins like albumin. Highly protein-bound drugs have a smaller free fraction available to produce effects, but they also persist longer in the body because bound drug is neither metabolized nor excreted. The volume of distribution (Vd) is a pharmacokinetic parameter that relates the total amount of drug in the body to its plasma concentration, providing insight into how extensively a drug leaves the bloodstream and enters tissues.

Metabolism, primarily carried out by the liver, chemically modifies drugs to make them more water-soluble and easier to excrete. Phase I reactions, catalyzed mainly by cytochrome P450 (CYP) enzymes, introduce or expose functional groups through oxidation, reduction, or hydrolysis. Phase II reactions conjugate the drug or its Phase I metabolite with a polar molecule such as glucuronic acid, sulfate, or glutathione, dramatically increasing water solubility. Some drugs are administered as inactive prodrugs that require metabolic activation to become effective; codeine, for example, must be converted to morphine by CYP2D6 to produce its analgesic effect.

Excretion removes the drug and its metabolites from the body. The kidneys are the primary excretory organs for most drugs, filtering them from the blood and eliminating them in urine. Renal excretion involves three processes: glomerular filtration (passive passage through the kidney's filtering apparatus), tubular secretion (active transport of drug from blood into the nephron), and tubular reabsorption (reuptake of drug from the nephron back into blood). Some drugs are excreted in bile and eliminated in feces, and a small fraction may be lost through sweat, saliva, or exhaled air. The half-life of a drug, the time required for its plasma concentration to decrease by half, reflects the combined rates of metabolism and excretion and determines how frequently a drug must be administered to maintain therapeutic levels.

Pharmacodynamics: What Drugs Do to the Body

Pharmacodynamics examines the biochemical and physiological effects of drugs and the mechanisms by which those effects are produced. Most drugs exert their effects by interacting with specific molecular targets in the body, predominantly proteins. These targets include receptors, enzymes, ion channels, and transport proteins.

Receptors are the most common drug targets. A receptor is a protein, usually located on the cell surface or inside the cell, that binds a specific signaling molecule (called a ligand) and triggers a cellular response. Drugs that bind to receptors and activate them are called agonists; drugs that bind but block activation are called antagonists. The concept of receptor-mediated drug action was first proposed by Paul Ehrlich in the early 1900s with his famous dictum: a substance does not work unless it is bound. John Newport Langley further developed receptor theory through his studies of how nicotine and curare produce opposite effects at the neuromuscular junction.

Enzymes are another major class of drug targets. Enzyme inhibitors block the catalytic activity of specific enzymes, reducing the production of particular metabolites or signaling molecules. Aspirin, for example, irreversibly inhibits cyclooxygenase (COX), the enzyme responsible for producing prostaglandins that cause inflammation, pain, and fever. Statins inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, reducing LDL cholesterol levels in the blood. ACE inhibitors block angiotensin-converting enzyme, preventing the formation of the vasoconstrictor angiotensin II and thereby lowering blood pressure.

Ion channels are pore-forming proteins that control the flow of ions across cell membranes. Local anesthetics like lidocaine block sodium channels in sensory neurons, preventing the propagation of pain signals. Calcium channel blockers like amlodipine reduce calcium influx into cardiac and smooth muscle cells, decreasing heart rate and dilating blood vessels. Benzodiazepines like diazepam enhance the activity of GABA-A receptor chloride channels, increasing inhibitory neurotransmission and producing sedation, anxiety relief, and muscle relaxation.

Transport proteins move molecules across cell membranes against their concentration gradients. Selective serotonin reuptake inhibitors (SSRIs) like fluoxetine block the serotonin transporter (SERT), preventing the reuptake of serotonin from the synaptic cleft and increasing serotonergic signaling. Proton pump inhibitors like omeprazole irreversibly block the hydrogen-potassium ATPase in gastric parietal cells, dramatically reducing stomach acid production.

Receptors, Agonists, and Antagonists

The interaction between a drug and its receptor follows the same principles as the interaction between an enzyme and its substrate. The drug binds to a specific site on the receptor through noncovalent forces including hydrogen bonds, ionic bonds, van der Waals forces, and hydrophobic interactions. The strength of this binding is described by the drug's affinity for the receptor, quantified as the dissociation constant (Kd), the concentration of drug at which half of the available receptors are occupied.

Not all drugs that bind to a receptor produce the same magnitude of response. A full agonist binds to the receptor and produces a maximal response, equivalent to the endogenous ligand. A partial agonist binds and activates the receptor but can only produce a submaximal response, no matter how high the concentration. Buprenorphine, used in opioid addiction treatment, is a partial agonist at the mu-opioid receptor: it produces enough activation to relieve withdrawal symptoms and cravings but has a ceiling effect that limits euphoria and respiratory depression compared to full agonists like morphine or fentanyl.

An antagonist binds to the receptor without activating it, blocking the endogenous ligand or other agonists from binding. Competitive antagonists bind to the same site as the agonist and can be overcome by increasing the agonist concentration. Naloxone, used to reverse opioid overdose, is a competitive antagonist at the mu-opioid receptor. Non-competitive antagonists bind to a different site (an allosteric site) and reduce the maximum response that the agonist can achieve, regardless of concentration. Inverse agonists bind to receptors that have constitutive (baseline) activity and reduce that activity below the unstimulated level.

Receptors are not static targets. Prolonged exposure to agonists can lead to desensitization (also called tachyphylaxis or tolerance), where the receptor becomes less responsive. Mechanisms include receptor phosphorylation, internalization into endosomes, and downregulation of receptor expression. Conversely, prolonged antagonist exposure can upregulate receptors, making cells more sensitive to agonists. This phenomenon explains why abruptly stopping beta-blocker therapy can cause rebound hypertension and tachycardia: the heart has upregulated its beta-adrenergic receptors in response to chronic blockade.

Dose-Response Relationships

The dose-response relationship is one of the most fundamental concepts in pharmacology. It describes how the magnitude of a drug's effect changes as the dose increases. When plotted on a graph with dose on the x-axis (often on a logarithmic scale) and response on the y-axis, most drugs produce a characteristic S-shaped (sigmoidal) curve.

Several key parameters define the dose-response curve. The EC50 (effective concentration 50%) is the concentration of drug that produces 50% of the maximum possible response, a measure of the drug's potency. A drug with a lower EC50 is more potent, meaning it produces a given effect at a lower concentration. The Emax is the maximum effect the drug can produce, a measure of its efficacy. A drug with a higher Emax is more efficacious. Potency and efficacy are independent properties: morphine is more potent than aspirin for pain relief (it works at lower doses), but this says nothing about their relative safety or clinical usefulness.

The therapeutic index quantifies a drug's safety margin. It is calculated as the ratio of the toxic dose (TD50 or LD50, the dose that produces toxicity or death in 50% of subjects) to the effective dose (ED50). A drug with a large therapeutic index, such as penicillin (therapeutic index greater than 100), has a wide margin between the dose that is effective and the dose that is dangerous. A drug with a narrow therapeutic index, such as warfarin, lithium, or digoxin, requires careful dose monitoring because the effective and toxic doses are close together. The therapeutic window is the range of plasma concentrations within which the drug is effective without being toxic.

Understanding dose-response relationships is essential for rational drug prescribing. Loading doses achieve therapeutic concentrations rapidly when the situation is urgent. Maintenance doses replace the drug lost through metabolism and excretion, keeping plasma levels within the therapeutic window. The dosing interval is determined by the drug's half-life: drugs with short half-lives require more frequent dosing or sustained-release formulations to avoid large fluctuations between peak and trough concentrations.

Drug Metabolism and Elimination

The liver is the body's primary drug-metabolizing organ, containing the highest concentration of metabolic enzymes and receiving a large fraction of cardiac output through both the hepatic artery and the portal vein. The portal vein carries blood directly from the gastrointestinal tract, meaning that orally administered drugs pass through the liver before reaching the systemic circulation. This first-pass metabolism can dramatically reduce a drug's bioavailability, the fraction of the administered dose that reaches the systemic circulation in active form. Nitroglycerin, for example, has such extensive first-pass metabolism that it is administered sublingually (under the tongue) to bypass the liver.

The cytochrome P450 (CYP) enzyme superfamily is responsible for the Phase I metabolism of approximately 75% of all clinically used drugs. Six CYP isoforms handle most drug metabolism: CYP3A4 (metabolizes about 50% of drugs), CYP2D6, CYP2C9, CYP2C19, CYP1A2, and CYP2E1. These enzymes exhibit genetic polymorphism, meaning that different individuals carry different versions of the genes encoding them. Someone who is a poor metabolizer for CYP2D6 will process codeine very slowly and get little pain relief, while an ultrarapid metabolizer will convert codeine to morphine so quickly that standard doses can cause dangerous respiratory depression.

Drug interactions at the metabolic level are clinically important. Enzyme inducers, such as rifampin, carbamazepine, and St. John's wort, increase the expression of CYP enzymes, accelerating the metabolism of co-administered drugs and potentially reducing their effectiveness. Enzyme inhibitors, such as ketoconazole, erythromycin, and grapefruit juice (which inhibits intestinal CYP3A4), slow the metabolism of other drugs, raising their plasma concentrations and increasing the risk of toxicity. The anticoagulant warfarin is notoriously susceptible to metabolic drug interactions because it is metabolized by multiple CYP enzymes and has a narrow therapeutic index.

Phase II conjugation reactions further transform drugs and Phase I metabolites by attaching polar groups. Glucuronidation, catalyzed by UDP-glucuronosyltransferases (UGTs), is the most common Phase II pathway. Acetaminophen (paracetamol) is normally eliminated safely through glucuronidation and sulfation, but when these pathways are saturated, as in overdose, a toxic metabolite called NAPQI accumulates and causes severe liver damage. The antidote, N-acetylcysteine, works by replenishing glutathione stores that neutralize NAPQI.

Major Drug Classes and How They Work

Pharmacology organizes drugs into classes based on their mechanisms of action, their therapeutic applications, or their chemical structures. Understanding these classes helps predict a drug's effects, side effects, and potential interactions.

Antibiotics kill bacteria or inhibit their growth by targeting structures and processes unique to prokaryotic cells. Beta-lactams (penicillins, cephalosporins) inhibit bacterial cell wall synthesis by blocking transpeptidase enzymes. Fluoroquinolones (ciprofloxacin, levofloxacin) inhibit bacterial DNA gyrase and topoisomerase IV, preventing DNA replication. Macrolides (azithromycin, erythromycin) bind the bacterial 50S ribosomal subunit and block protein synthesis. Aminoglycosides (gentamicin, tobramycin) bind the 30S ribosomal subunit and cause misreading of mRNA.

Analgesics relieve pain through different mechanisms depending on the class. Non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and naproxen inhibit cyclooxygenase enzymes, reducing prostaglandin synthesis and thereby decreasing inflammation, pain, and fever. Opioid analgesics like morphine and oxycodone activate mu-opioid receptors in the central nervous system, modulating pain perception at the level of the spinal cord and brain. Acetaminophen's mechanism remains incompletely understood but is thought to involve inhibition of COX enzymes in the central nervous system and activation of descending serotonergic pain-inhibition pathways.

Cardiovascular drugs target the heart and blood vessels. Beta-blockers (metoprolol, atenolol) block beta-adrenergic receptors, reducing heart rate and myocardial oxygen demand. ACE inhibitors (lisinopril, enalapril) and angiotensin receptor blockers (losartan, valsartan) reduce angiotensin II signaling, lowering blood pressure and reducing cardiac remodeling in heart failure. Diuretics (furosemide, hydrochlorothiazide) increase urine output by acting on various segments of the renal nephron, reducing blood volume and pressure.

Psychotropic drugs modify brain chemistry to treat mental health conditions. SSRIs increase serotonin availability in synapses. Typical antipsychotics (haloperidol) block dopamine D2 receptors, while atypical antipsychotics (olanzapine, quetiapine) also antagonize serotonin 5-HT2A receptors. Benzodiazepines enhance GABA-A receptor function, producing anxiolytic, sedative, and anticonvulsant effects.

Why Drugs Have Side Effects

No drug is perfectly selective. Side effects arise because the molecular targets that drugs act upon are often present in multiple tissues, and because drugs may interact with unintended targets at higher concentrations. Aspirin's inhibition of COX enzymes relieves pain and inflammation but also reduces the protective prostaglandins that maintain the stomach lining, leading to gastrointestinal irritation and ulcers. Antihistamines that cross the blood-brain barrier block histamine H1 receptors in the central nervous system, causing drowsiness as an unwanted side effect of allergy treatment.

The distinction between side effects and adverse drug reactions is important. Side effects are predictable, dose-dependent extensions of a drug's pharmacological activity (Type A reactions). They are generally mild, reversible, and manageable with dose adjustment. Adverse drug reactions can also be unpredictable and unrelated to the drug's primary mechanism (Type B reactions), such as drug allergies (immune-mediated hypersensitivity) and idiosyncratic reactions based on individual genetic variation. Type B reactions are less common but potentially more serious because they cannot be predicted from the drug's known pharmacology.

Drug selectivity is a central goal of modern drug design. Newer-generation antihistamines like cetirizine and loratadine were specifically engineered to have low brain penetration, reducing sedation while maintaining antiallergy efficacy. COX-2 selective inhibitors (celecoxib) were designed to spare the COX-1 isoform that protects the stomach, though the clinical reality proved more nuanced when rofecoxib (Vioxx) was withdrawn due to increased cardiovascular risk. These examples illustrate both the potential and the limitations of designing drugs for improved selectivity.

How New Drugs Are Developed

Bringing a new drug from initial discovery to market approval is a long, expensive, and uncertain process. On average, it takes 10 to 15 years and costs over $1 billion, with the vast majority of candidate molecules failing during development. The process begins with target identification, where researchers select a molecular target (a receptor, enzyme, or pathway) believed to play a role in a disease. Lead discovery then identifies chemical compounds that interact with that target, often by screening large compound libraries using high-throughput assays.

Preclinical testing evaluates the lead compound's pharmacokinetics, toxicity, and efficacy in cell-based assays and animal models. Only compounds that demonstrate acceptable safety and promising efficacy proceed to human testing. Clinical trials occur in three phases: Phase I tests safety and pharmacokinetics in a small group of healthy volunteers (typically 20 to 100). Phase II tests efficacy and side effects in patients with the target disease (typically 100 to 300). Phase III confirms efficacy in large, randomized, controlled trials (typically 1,000 to 3,000 patients) comparing the new drug to existing treatments or placebo.

Regulatory agencies such as the FDA (United States), EMA (European Union), and PMDA (Japan) review the complete data package and decide whether to approve the drug for sale. Post-approval Phase IV surveillance monitors long-term safety in the broader population, since rare side effects may only become apparent when millions of patients take the drug. This rigorous pipeline exists because the history of pharmacology includes tragic examples of inadequately tested drugs causing widespread harm, most notably thalidomide in the 1960s, which caused severe birth defects when prescribed to pregnant women for morning sickness.

Pharmacogenomics and Personalized Medicine

Pharmacogenomics studies how genetic variation affects individual responses to drugs. It is now well established that polymorphisms in drug-metabolizing enzymes, drug transporters, and drug targets can explain much of the variability observed in drug efficacy and toxicity across patients. The CYP2D6 gene alone has over 100 known allelic variants, producing metabolizer phenotypes ranging from poor (little or no enzyme activity) to ultrarapid (excessive activity). These differences have real clinical consequences: poor CYP2D6 metabolizers get no pain relief from codeine because they cannot convert it to its active metabolite morphine, while ultrarapid metabolizers may experience overdose symptoms at standard doses.

Pharmacogenomic testing is increasingly incorporated into clinical practice. The FDA has included pharmacogenomic information in the labeling of over 400 drugs. Before prescribing abacavir (an HIV drug), clinicians now routinely test for the HLA-B*5701 allele, which is associated with a severe hypersensitivity reaction. Patients with certain DPYD gene variants are at high risk of life-threatening toxicity from the chemotherapy drug fluorouracil. Testing for VKORC1 and CYP2C9 variants helps predict the optimal starting dose of warfarin, reducing the risk of both bleeding and inadequate anticoagulation.

The vision of personalized medicine, where drug selection and dosing are tailored to each patient's genetic profile, is gradually becoming reality. As genetic testing becomes faster and cheaper, pharmacogenomics promises to reduce trial-and-error prescribing, minimize adverse drug reactions, and improve treatment outcomes across virtually every area of medicine.

Explore Pharmacology Topics

Foundations

Drug Targets and Mechanisms

How Specific Drugs Work

Drug Discovery and the Future